세포 및 유전자 치료 제조 품질관리(QC) 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 치료 유형별, 제공 내용별, 프로세스별, 기술별, 용도별, 지역별＆경쟁(2021-2031년)

Cell and Gene Therapy Manufacturing QC Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type, By Offering, By Process, By Technology, By Application, By Region & Competition, 2021-2031F

US $ 4,500 ￦ 6,722,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 8,215,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,950,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 세포 및 유전자 치료 제조 품질관리(QC) 시장은 2025년 13억 5,000만 달러에서 2031년까지 20억 1,000만 달러로 성장하고, CAGR 6.87%를 나타낼 것으로 예측됩니다.

이 분야는 첨단 의료제품의 안전성, 유효성, 순도, 순도, 동일성을 검증하기 위한 엄격한 분석 시험과 규제 준수 프로세스에 중점을 두고 있습니다. 이 시장의 성장은 주로 임상시험 건수의 급증과 종양학 및 희귀 유전질환 치료제의 규제 승인률 증가에 힘입은 바 큽니다. 이러한 요인들로 인해 생물학적 제제의 자연적 변동성을 관리하면서 상업적 규모 확대 시 엄격한 안전 기준을 충족하기 위한 종합적인 품질 보증 프레임워크를 도입하는 것이 필수적입니다.

시장 개요
예측 기간	2027-2031년
시장 규모 : 2025년	13억 5,000만 달러
시장 규모 : 2031년	20억 1,000만 달러
CAGR : 2026-2031년	6.87%
가장 성장이 빠른 부문	유전자 치료
최대 시장	북미

미국 유전자 및 세포치료학회 자료에 따르면, 2024년 기준 전 세계 개발 파이프라인에는 4,000개 이상의 치료 후보물질이 존재하며, 전문적인 시험 프로토콜에 대한 수요가 크게 증가하고 있습니다. 이러한 견고한 성장 궤도에도 불구하고, 시장은 표준화된 효능 측정법 개발에 따른 기술적 복잡성과 높은 비용이라는 심각한 장벽에 직면해 있습니다. 이러한 문제들은 생산 일정을 장기화시키고, 전체 매출 원가를 상승시키는 경향이 있어 시장 확대의 제약 요인으로 작용하고 있습니다.

시장 성장 촉진요인

바이오의약품 연구개발에 대한 막대한 자금 유입과 투자가 세포-유전자치료(CGT) 분야의 첨단 품질관리 기법의 도입을 근본적으로 가속화하고 있습니다. 개발자들이 복잡한 치료법의 상용화를 위해 임상시험의 진행과 견고하고 확장 가능한 제조 및 시험 인프라 구축에 막대한 자금이 투입되고 있습니다. 이러한 재무구조를 통해 기업은 고급 분석 장비를 도입하고, 규제 준수에 필요한 신속한 시험 방법 검증을 할 수 있게 되었습니다. 재생의료연합(Alliance for Regenerative Medicine)에 따르면, 2024년 10월에 이 분야의 자금 조달이 다시 활성화되어 상반기에만 전 세계 투자액이 109억 달러에 달했다고 합니다. 이 자금은 제조상의 병목현상을 극복하고 후기 단계 후보물질 증가에 따른 품질관리의 진화에 대응하기 위해 매우 중요합니다.

두 번째 중요한 촉진요인은 품질 관리 워크플로우에 자동화와 디지털화를 통합하는 것입니다. 이는 업계가 요구하는 정확도 향상과 오류 감소에 직접적으로 대응하는 것입니다. 제조업체는 노동 집약적인 수동 테스트를 자동화 플랫폼으로 대체함으로써 데이터의 무결성을 높이고 무균 및 유효성 테스트 결과 보고 시간을 단축하고 있습니다. 이러한 변화는 자동화 생산 능력을 확보하기 위한 대형 제약사들의 제휴에서 두드러지게 나타나고 있습니다. 예를 들어, 2024년 4월 Fierce Pharma지 보도에 따르면, 브리스톨 마이어스 스퀴브(Bristol-Myers Squibb)는 셀레아레스의 완전 자동화 플랫폼에 대한 독점적 생산 능력을 확보하기 위해 3억 8,000만 달러 규모의 계약을 체결하였습니다. 이러한 추세는 규제 측면의 발전으로 인해 더욱 강화되고 있습니다. 예를 들어, PharmaBoardroom이 2024년 4월에 보도한 바와 같이, 2023년에는 세포 및 유전자 치료제의 FDA 승인 건수가 7건으로 역대 최다를 기록할 것으로 예측됩니다. 상업적 수요를 충족시키기 위해 자동화되고 규정을 준수하는 품질 관리 솔루션이 절실히 필요하다는 점을 강조하고 있습니다.

시장의 과제

표준화된 효능 시험법 개발은 복잡한 기술 요건과 높은 비용을 수반하며, 이는 세계 세포-유전자치료제 제조 품질 관리 시장의 성장에 큰 장벽이 되고 있습니다. 첨단 치료법에 내재된 생물학적 변동성이 크기 때문에 제조업체는 기성품 표준을 사용하지 않고 제품의 효능을 검증하기 위해 맞춤형 시험 프로토콜을 설계해야 하는 경우가 많습니다. 이러한 표준화의 부족은 값비싸고 힘든 개발 주기를 필요로 하고, 제품 원가(COGS)를 크게 증가시키며, 생산 일정을 연장시킵니다. 이러한 문제들은 화학, 제조, 관리(CMC)의 미비로 인해 제품이 상업화 단계에 진입하는 것을 방해하고, 대량의 품질 관리 시험을 통한 수익 창출을 막고, 규제상의 지연을 초래하는 경우가 많습니다.

2024년, 재생의료연합(Alliance for Regenerative Medicine)은 전 세계적으로 최대 17개의 새로운 세포 및 유전자 치료제가 규제 승인을 받을 것으로 예상하고 있으며, 이는 상업적 제품의 유입을 의미하며, 품질 관리 시스템에 심각한 압력을 가하고 있습니다. 그러나 현재의 효능 측정 방법의 비효율성으로 인해 병목현상이 발생하여 잠재적인 처리 능력을 저해하고 있습니다. 그 결과, 높은 시험 비용과 기술적 장벽으로 인해 치료 후보물질의 확장 가능한 상업적 생산으로의 전환이 지연되어 시장 확대에 직접적으로 방해가 되고 있습니다.

시장 동향

업계에서 눈에 띄는 트렌드로는 복잡한 바이러스 벡터 및 세포치료제 특성평가라는 기술적 요구를 배경으로 전문적인 품질관리 시험을 위탁개발제조기관(CDMO)에 아웃소싱하는 의존도가 높아지고 있습니다. 바이오 제약사들은 모든 치료법에 대응하는 고비용의 자체 시험 체계를 구축하는 대신 CDMO가 보유한 검증된 규제 대응 노하우와 확장 가능한 인프라를 활용하여 배치리스에 박차를 가하고 있습니다. 이러한 제조 및 테스트 리소스의 통합은 시장 동향에서도 알 수 있습니다. 예를 들어, 바이오파마다이브가 보도한 2024년 12월 노보홀딩스의 카탈런트(Catalent)에 대한 165억 달러 규모의 인수는 첨단 치료제 생산 증가하는 양과 복잡성을 관리하기 위해 업계가 외부 파트너에 대한 전략적 의존도를 높이고 있다는 것을 보여줍니다.

동시에 예측 품질 분석에 인공지능을 적용하는 것이 단순한 디지털화를 넘어 업스트림 공정과 다운스트림 공정 모두를 최적화하는 변혁의 힘으로 부상하고 있습니다. 제조업체들은 머신러닝 알고리즘을 활용하여 바이오리액터의 방대한 데이터 세트를 분석하여 배치 불량을 유발하기 전에 심각한 품질 편차나 대사 변화를 식별하여 고가의 재고를 보호하고 있습니다. 자가유래 치료제의 생산에는 막대한 비용이 수반되기 때문에 이러한 예측 능력은 경제적으로 필수적인 요소가 되고 있습니다. 2025년 9월 IT Brief Australia에 따르면, 단일 세포치료제 배치가 50만 달러 이상의 생산 오류에 따른 막대한 재정적 위험이 상업적 타당성을 위해 AI 기반 실시간 모니터링 도입을 추진하고 있다고 합니다.

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 세포 및 유전자 치료 제조 QC 시장 전망

제6장 북미의 세포 및 유전자 치료 제조 QC 시장 전망

제7장 유럽의 세포 및 유전자 치료 제조 QC 시장 전망

제8장 아시아태평양의 세포 및 유전자 치료 제조 QC 시장 전망

제9장 중동 및 아프리카의 세포 및 유전자 치료 제조 QC 시장 전망

제10장 남미의 세포 및 유전자 치료 제조 QC 시장 전망

제11장 시장 역학

제12장 시장 동향과 발전

제13장 세계의 세포 및 유전자 치료 제조 QC 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

제15장 경쟁 구도

제16장 전략적 제안

제17장 회사 소개 및 면책조항

LSH

영문 목차

영문목차

The Global Cell and Gene Therapy Manufacturing QC Market is projected to expand from USD 1.35 Billion in 2025 to USD 2.01 Billion by 2031, reflecting a compound annual growth rate of 6.87%. This sector focuses on stringent analytical testing and regulatory adherence processes designed to verify the safety, potency, purity, and identity of advanced medicinal products. The market is primarily underpinned by a surge in clinical trial volumes and an increasing rate of regulatory approvals for therapies targeting oncology and rare genetic disorders. These drivers necessitate the implementation of comprehensive quality assurance frameworks to manage the natural variability of biologic materials while ensuring rigorous safety standards are met during commercial scale-up.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 1.35 Billion
Market Size 2031	USD 2.01 Billion
CAGR 2026-2031	6.87%
Fastest Growing Segment	Gene Therapy
Largest Market	North America

Data from the American Society of Gene and Cell Therapy indicates that in 2024, the global development pipeline contained more than 4,000 therapeutic candidates, generating substantial demand for specialized testing protocols. Despite this robust growth trajectory, the market faces a significant obstacle regarding the technical complexity and high costs associated with creating standardized potency assays. These challenges often prolong production timelines and inflate the overall cost of goods sold, acting as a constraint on broader market expansion.

Market Driver

Significant capital inflows and investments in biopharmaceutical R&D are fundamentally accelerating the adoption of advanced quality control measures within the cell and gene therapy (CGT) sector. As developers strive to commercialize complex therapies, vast financial resources are being allocated to clinical progression as well as the establishment of robust, scalable manufacturing and testing infrastructures. This financial strength enables companies to acquire high-end analytical instruments and validate the rapid testing methods required for regulatory compliance. According to the Alliance for Regenerative Medicine, the sector saw a resurgence in financing in October 2024, with global investments reaching $10.9 billion in the first half of the year alone, funding that is crucial for overcoming manufacturing bottlenecks and aligning quality control evolution with the increasing number of late-stage candidates.

A second critical driver is the integration of automation and digitalization into quality control workflows, which directly addresses the industry's need for precision and error reduction. By replacing labor-intensive manual assays with automated platforms, manufacturers are enhancing data integrity and reducing turnaround times for sterility and potency results. This shift is exemplified by major pharmaceutical collaborations aiming to secure automated production capacities; for instance, Fierce Pharma reported in April 2024 that Bristol Myers Squibb signed a $380 million deal to reserve exclusive capacity on Cellares' fully automated platform. This trend is further reinforced by regulatory successes, such as the record seven new FDA approvals for cell and gene therapies in 2023 noted by PharmaBoardroom in April 2024, underscoring the urgency for automated, compliant QC solutions to meet commercial demand.

Market Challenge

The intricate technical requirements and high costs involved in developing standardized potency assays constitute a formidable barrier to the growth of the Global Cell and Gene Therapy Manufacturing QC Market. Due to the significant biological variability inherent in advanced therapies, manufacturers are often compelled to design bespoke testing protocols to verify product potency rather than utilizing off-the-shelf standards. This lack of standardization requires expensive, labor-intensive development cycles that significantly increase the overall cost of goods sold (COGS) and extend production timelines. These issues frequently lead to regulatory delays, as deficiencies in Chemistry, Manufacturing, and Controls (CMC) can prevent products from advancing to the commercial stage where high-volume quality control testing generates revenue.

In 2024, the Alliance for Regenerative Medicine anticipated up to 17 regulatory approvals for new cell and gene therapies globally, signaling an influx of commercial products that places acute pressure on quality control systems. However, the inefficiency of current potency assays creates a bottleneck that stifles this potential throughput. Consequently, market expansion is directly impeded, as high testing costs and technical hurdles slow the transition of therapeutic candidates into scalable commercial production.

Market Trends

A dominant trend in the industry is the increasing reliance on outsourcing specialized QC assays to Contract Development and Manufacturing Organizations (CDMOs), driven by the technical demands of characterizing complex viral vectors and cell therapies. Rather than constructing expensive in-house testing capabilities for every modality, biopharmaceutical companies are leveraging the established regulatory expertise and scalable infrastructure of CDMOs to accelerate batch release. This consolidation of manufacturing and testing resources is illustrated by significant market movements, such as Novo Holdings' pivotal $16.5 billion acquisition of Catalent in December 2024, as reported by BioPharma Dive, which underscores the sector's strategic reliance on external partners to manage the growing volume and complexity of advanced therapeutic production.

Simultaneously, the application of artificial intelligence for predictive quality analytics is emerging as a transformative force, moving beyond simple digitization to optimize both upstream and downstream processes. Manufacturers are utilizing machine learning algorithms to analyze vast datasets from bioreactors, allowing for the identification of critical quality deviations and metabolic shifts before they result in batch failure, thereby protecting expensive inventory. This predictive capability is becoming financially imperative given the high costs associated with manufacturing autologous treatments; according to IT Brief Australia in September 2025, the substantial financial risk of production errors-where a single cell therapy batch can cost upwards of $500,000-is driving the adoption of AI-driven real-time monitoring for commercial viability.

Key Market Players

• Bio-Techne Corporation
• Biomerieux SA
• F. Hoffmann-La Roche Ltd
• Lonza Group Ltd.
• Miltenyi Biotec India Pvt Ltd.
• Sartorius AG
• Thermo Fisher Scientific Inc.
• AGC Inc.
• Charles River Laboratories International, Inc.
• Merck KGaA

Report Scope

In this report, the Global Cell and Gene Therapy Manufacturing QC Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell and Gene Therapy Manufacturing QC Market, By Therapy Type

• Cell Therapy
• Gene Therapy

Cell and Gene Therapy Manufacturing QC Market, By Offering

• Instruments
• Consumables
• Others

Cell and Gene Therapy Manufacturing QC Market, By Process

• Raw Material Preparation
• Upstream Processing
• Downstream Processing
• Packaging

Cell and Gene Therapy Manufacturing QC Market, By Technology

• Polymerase Chain Reaction (PCR)
• Flow Cytometry
• Limulus Amebocyte Lysate (LAL)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Chromatography
• Mass Spectrometry
• Western Blotting
• Next-Generation Sequencing (NGS)
• Electrophoresis
• Others

Cell and Gene Therapy Manufacturing QC Market, By Application

• Safety Testing
• Potency Testing
• Identity Testing
• Stability and Genetic Fidelity Testing
• Others

Cell and Gene Therapy Manufacturing QC Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell and Gene Therapy Manufacturing QC Market.

Available Customizations:

Global Cell and Gene Therapy Manufacturing QC Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell and Gene Therapy Manufacturing QC Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (Cell Therapy, Gene Therapy)
  • 5.2.2. By Offering (Instruments, Consumables, Others)
  • 5.2.3. By Process (Raw Material Preparation, Upstream Processing, Downstream Processing, Packaging)
  • 5.2.4. By Technology (Polymerase Chain Reaction (PCR), Flow Cytometry, Limulus Amebocyte Lysate (LAL), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Mass Spectrometry, Western Blotting, Next-Generation Sequencing (NGS), Electrophoresis, Others)
  • 5.2.5. By Application (Safety Testing, Potency Testing, Identity Testing, Stability and Genetic Fidelity Testing, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Cell and Gene Therapy Manufacturing QC Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Offering
  • 6.2.3. By Process
  • 6.2.4. By Technology
  • 6.2.5. By Application
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Offering
      • 6.3.1.2.3. By Process
      • 6.3.1.2.4. By Technology
      • 6.3.1.2.5. By Application
  • 6.3.2. Canada Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Offering
      • 6.3.2.2.3. By Process
      • 6.3.2.2.4. By Technology
      • 6.3.2.2.5. By Application
  • 6.3.3. Mexico Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Offering
      • 6.3.3.2.3. By Process
      • 6.3.3.2.4. By Technology
      • 6.3.3.2.5. By Application

7. Europe Cell and Gene Therapy Manufacturing QC Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Offering
  • 7.2.3. By Process
  • 7.2.4. By Technology
  • 7.2.5. By Application
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Offering
      • 7.3.1.2.3. By Process
      • 7.3.1.2.4. By Technology
      • 7.3.1.2.5. By Application
  • 7.3.2. France Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Offering
      • 7.3.2.2.3. By Process
      • 7.3.2.2.4. By Technology
      • 7.3.2.2.5. By Application
  • 7.3.3. United Kingdom Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Offering
      • 7.3.3.2.3. By Process
      • 7.3.3.2.4. By Technology
      • 7.3.3.2.5. By Application
  • 7.3.4. Italy Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Offering
      • 7.3.4.2.3. By Process
      • 7.3.4.2.4. By Technology
      • 7.3.4.2.5. By Application
  • 7.3.5. Spain Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Offering
      • 7.3.5.2.3. By Process
      • 7.3.5.2.4. By Technology
      • 7.3.5.2.5. By Application

8. Asia Pacific Cell and Gene Therapy Manufacturing QC Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Offering
  • 8.2.3. By Process
  • 8.2.4. By Technology
  • 8.2.5. By Application
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Offering
      • 8.3.1.2.3. By Process
      • 8.3.1.2.4. By Technology
      • 8.3.1.2.5. By Application
  • 8.3.2. India Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Offering
      • 8.3.2.2.3. By Process
      • 8.3.2.2.4. By Technology
      • 8.3.2.2.5. By Application
  • 8.3.3. Japan Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Offering
      • 8.3.3.2.3. By Process
      • 8.3.3.2.4. By Technology
      • 8.3.3.2.5. By Application
  • 8.3.4. South Korea Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Offering
      • 8.3.4.2.3. By Process
      • 8.3.4.2.4. By Technology
      • 8.3.4.2.5. By Application
  • 8.3.5. Australia Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Offering
      • 8.3.5.2.3. By Process
      • 8.3.5.2.4. By Technology
      • 8.3.5.2.5. By Application

9. Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Offering
  • 9.2.3. By Process
  • 9.2.4. By Technology
  • 9.2.5. By Application
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell and Gene Therapy Manufacturing QC Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Offering
      • 9.3.1.2.3. By Process
      • 9.3.1.2.4. By Technology
      • 9.3.1.2.5. By Application
  • 9.3.2. UAE Cell and Gene Therapy Manufacturing QC Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Offering
      • 9.3.2.2.3. By Process
      • 9.3.2.2.4. By Technology
      • 9.3.2.2.5. By Application
  • 9.3.3. South Africa Cell and Gene Therapy Manufacturing QC Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Offering
      • 9.3.3.2.3. By Process
      • 9.3.3.2.4. By Technology
      • 9.3.3.2.5. By Application

10. South America Cell and Gene Therapy Manufacturing QC Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By Offering
  • 10.2.3. By Process
  • 10.2.4. By Technology
  • 10.2.5. By Application
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell and Gene Therapy Manufacturing QC Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Offering
      • 10.3.1.2.3. By Process
      • 10.3.1.2.4. By Technology
      • 10.3.1.2.5. By Application
  • 10.3.2. Colombia Cell and Gene Therapy Manufacturing QC Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Offering
      • 10.3.2.2.3. By Process
      • 10.3.2.2.4. By Technology
      • 10.3.2.2.5. By Application
  • 10.3.3. Argentina Cell and Gene Therapy Manufacturing QC Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Offering
      • 10.3.3.2.3. By Process
      • 10.3.3.2.4. By Technology
      • 10.3.3.2.5. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell and Gene Therapy Manufacturing QC Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bio-Techne Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Biomerieux SA
• 15.3. F. Hoffmann-La Roche Ltd
• 15.4. Lonza Group Ltd.
• 15.5. Miltenyi Biotec India Pvt Ltd.
• 15.6. Sartorius AG
• 15.7. Thermo Fisher Scientific Inc.
• 15.8. AGC Inc.
• 15.9. Charles River Laboratories International, Inc.
• 15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer

관련자료